These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37060367)

  • 1. Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand.
    Derks YHW; Schilham MGM; Rijpkema M; Smeets EMM; Amatdjais-Groenen HIV; Kip A; van Lith SAM; van de Kamp J; Sedelaar JPM; Somford DM; Simons M; Laverman P; Gotthardt M; Löwik DWPM; Heskamp S; Lütje S
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2872-2884. PubMed ID: 37060367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer.
    Derks YHW; van Lith SAM; Amatdjais-Groenen HIV; Wouters LWM; Kip A; Franssen GM; Laverman P; Löwik DWPM; Heskamp S; Rijpkema M
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2425-2435. PubMed ID: 35029739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors.
    Lütje S; Heskamp S; Franssen GM; Frielink C; Kip A; Hekman M; Fracasso G; Colombatti M; Herrmann K; Boerman OC; Gotthardt M; Rijpkema M
    Theranostics; 2019; 9(10):2924-2938. PubMed ID: 31244933
    [No Abstract]   [Full Text] [Related]  

  • 4. Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer.
    Derks YHW; Rijpkema M; Amatdjais-Groenen HIV; Kip A; Franssen GM; Sedelaar JPM; Somford DM; Simons M; Laverman P; Gotthardt M; Löwik DWPM; Lütje S; Heskamp S
    Theranostics; 2021; 11(4):1527-1541. PubMed ID: 33408764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
    Wang X; Tsui B; Ramamurthy G; Zhang P; Meyers J; Kenney ME; Kiechle J; Ponsky L; Basilion JP
    Mol Cancer Ther; 2016 Aug; 15(8):1834-44. PubMed ID: 27297866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation.
    Capozza M; Stefania R; Dinatale V; Bitonto V; Conti L; Grange C; Skovronova R; Terreno E
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Circulating Prostate-Specific Membrane Antigen-Targeted NIR Phototheranostic Agent.
    Overchuk M; Damen MPF; Harmatys KM; Pomper MG; Chen J; Zheng G
    Photochem Photobiol; 2020 May; 96(3):718-724. PubMed ID: 31742696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strain-Promoted Azide-Alkyne Cycloaddition-Based PSMA-Targeting Ligands for Multimodal Intraoperative Tumor Detection of Prostate Cancer.
    Derks YHW; Rijpkema M; Amatdjais-Groenen HIV; Loeff CC; de Roode KE; Kip A; Laverman P; Lütje S; Heskamp S; Löwik DWPM
    Bioconjug Chem; 2022 Jan; 33(1):194-205. PubMed ID: 34957825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
    Ngen EJ; Chen Y; Azad BB; Boinapally S; Jacob D; Lisok A; Shen C; Hossain MS; Jin J; Bhujwalla ZM; Pomper MG; Banerjee SR
    Nanotheranostics; 2021; 5(2):182-196. PubMed ID: 33564617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A PSMA-targeted theranostic agent for photodynamic therapy.
    Chen Y; Chatterjee S; Lisok A; Minn I; Pullambhatla M; Wharram B; Wang Y; Jin J; Bhujwalla ZM; Nimmagadda S; Mease RC; Pomper MG
    J Photochem Photobiol B; 2017 Feb; 167():111-116. PubMed ID: 28063300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic Therapy Is an Effective Adjuvant Therapy for Image-Guided Surgery in Prostate Cancer.
    Wang X; Ramamurthy G; Shirke AA; Walker E; Mangadlao J; Wang Z; Wang Y; Shan L; Schluchter MD; Dong Z; Brady-Kalnay SM; Walker NK; Gargesha M; MacLennan G; Luo D; Sun R; Scott B; Roy D; Li J; Basilion JP
    Cancer Res; 2020 Jan; 80(2):156-162. PubMed ID: 31719100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Synergistic Strategy Combining Chemotherapy and Photodynamic Therapy to Eradicate Prostate Cancer.
    Shirke AA; Walker E; Chavali S; Ramamurthy G; Zhang L; Panigrahi A; Basilion JP; Wang X
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
    Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
    Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.
    Kularatne SA; Wang K; Santhapuram HK; Low PS
    Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
    Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer.
    Wang X; Sun R; Wang J; Li J; Walker E; Shirke A; Ramamurthy G; Shan L; Luo D; Carmon L; Basilion JP
    Theranostics; 2022; 12(5):2335-2350. PubMed ID: 35265213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.